Cytomed Therapeutics Announced That The Intellectual Property Corporation Of Malaysia Has Granted A Patent For Its Chimeric Antigen Receptor Gamma Delta T Cell Technology, Which Targets Solid And Hematological Tumors
Cytomed Therapeutics宣布，马来西亚知识产权公司已批准其针对实体肿瘤和血液学肿瘤的嵌合抗原受体伽玛德尔塔T细胞技术的专利